Ccr

76%

14%

Intolerance

3%

31%

Progressive disease

3%

8.5%

CCR, complete cytogenetic response; CHR, complete hematologic response; MCR, major cytogenetic response (Philadelphia chromosome-positive metaphases<35%). Intolerance leading to discontinuation of first-line therapy. Progressive disease to accelerated phase or blast crisis. All of these differences are highly statistically significant with p<0.001.

CCR, complete cytogenetic response; CHR, complete hematologic response; MCR, major cytogenetic response (Philadelphia chromosome-positive metaphases<35%). Intolerance leading to discontinuation of first-line therapy. Progressive disease to accelerated phase or blast crisis. All of these differences are highly statistically significant with p<0.001.

genetic responses, tolerance of therapy, and freedom from disease progression (O'Brien et al. 2003). Despite the fact that 76% of patients randomized to imatinib achieved a complete cytogenetic response, the majority of these patients had detectable leukemia using BCR-ABL transcripts as analyzed by reverse transcriptase-polymerase chain reaction (RT-PCR) (Hughes et al. 2002). When analyzed by log reduction in BCR-ABL transcript levels, 39% of patients achieved at least a 3-log reduction in BCR-ABL levels, but only 13% and 3% achieved a 4- and 5-log reduction, respectively.

Was this article helpful?

0 0

Post a comment